Amova Asset Management Americas Inc. cut its position in shares of Pacific Biosciences of California, Inc. (NASDAQ:PACB – Free Report) by 9.9% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 7,037,987 shares of the biotechnology company’s stock after selling 770,593 shares during the period. Amova Asset Management Americas Inc. owned 2.27% of Pacific Biosciences of California worth $9,220,000 at the end of the most recent quarter.
A number of other institutional investors and hedge funds also recently modified their holdings of PACB. UBS Group AG grew its stake in shares of Pacific Biosciences of California by 111.8% during the fourth quarter. UBS Group AG now owns 3,171,546 shares of the biotechnology company’s stock worth $5,931,000 after buying an additional 1,674,320 shares during the last quarter. Casdin Capital LLC increased its holdings in shares of Pacific Biosciences of California by 483.6% during the fourth quarter. Casdin Capital LLC now owns 4,223,767 shares of the biotechnology company’s stock worth $7,898,000 after buying an additional 3,500,000 shares in the last quarter. Main Street Research LLC bought a new position in shares of Pacific Biosciences of California in the 1st quarter valued at $201,000. Hartline Investment Corp lifted its stake in shares of Pacific Biosciences of California by 122.6% in the 1st quarter. Hartline Investment Corp now owns 69,000 shares of the biotechnology company’s stock valued at $91,000 after acquiring an additional 38,000 shares during the last quarter. Finally, AdvisorNet Financial Inc boosted its holdings in shares of Pacific Biosciences of California by 6.2% during the 1st quarter. AdvisorNet Financial Inc now owns 142,057 shares of the biotechnology company’s stock valued at $188,000 after acquiring an additional 8,290 shares in the last quarter.
Analyst Upgrades and Downgrades Several research analysts have recently issued reports on PACB shares. Barclays upped their price objective on Pacific Biosciences of California from $1.00 to $1.50 and gave the company an “underweight” rating in a research note on Monday, May 11th. Zacks Research lowered shares of Pacific Biosciences of California from a “strong-buy” rating to a “hold” rating in a report on Monday, April 20th. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of Pacific Biosciences of California in a research report on Tuesday, April 21st. One analyst has rated the stock with a Buy rating, two have assigned a Hold rating and two have given a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Reduce” and a consensus price target of $1.83.
View Our Latest Stock Analysis on PACB
Pacific Biosciences of California Price Performance NASDAQ PACB opened at $1.36 on Tuesday. The stock has a market capitalization of $422.42 million, a price-to-earnings ratio of -3.16 and a beta of 2.29. Pacific Biosciences of California, Inc. has a one year low of $1.09 and a one year high of $2.73. The business’s fifty day moving average is $1.43 and its 200-day moving average is $1.62.
Pacific Biosciences of California (NASDAQ:PACB – Get Free Report) last announced its quarterly earnings data on Thursday, May 7th. The biotechnology company reported ($0.12) earnings per share for the quarter, topping the consensus estimate of ($0.17) by $0.05. The company had revenue of $37.18 million during the quarter, compared to analyst estimates of $39.94 million. Pacific Biosciences of California had a negative return on equity of 571.06% and a negative net margin of 80.35%. Research analysts expect that Pacific Biosciences of California, Inc. will post -0.5 EPS for the current fiscal year.
About Pacific Biosciences of California (Free Report)
Pacific Biosciences of California, Inc develops, manufactures and sells high-performance DNA sequencing systems for genetic and genomic analysis. The company’s proprietary single-molecule, real-time (SMRT) sequencing technology is designed to enable long-read sequencing, offering high accuracy for applications such as de novo genome assembly, transcriptome characterization and structural variation analysis. Pacific Biosciences markets a suite of instruments, including the Sequel and Sequel IIe systems, alongside reagents, consumables and data analysis software to support a range of life science research.
Founded in 2004 and headquartered in Menlo Park, California, Pacific Biosciences has expanded its global reach by serving academic institutions, biotechnology and pharmaceutical companies, and government research centers across North America, Europe and Asia.
See Also Five stocks we like better than Pacific Biosciences of California The Ugliest Stocks in the Market Just Got a Very Expensive Vote of Confidence Is Domino’s Stock Serving Up a Buying Opportunity? A $1T Black Hole: SpaceX Eyes Pentagon AI to Break Free Why Gold Miners Could Be the Market’s Biggest Comeback Story Want to see what other hedge funds are holding PACB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pacific Biosciences of California, Inc. (NASDAQ:PACB – Free Report).
Receive News & Ratings for Pacific Biosciences of California Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacific Biosciences of California and related companies with MarketBeat.com's FREE daily email newsletter.
« PREVIOUS HEADLINEPrime Medicine, Inc. $PRME Shares Sold by Amova Asset Management Americas Inc.
NEXT HEADLINE »Amova Asset Management Americas Inc. Has $13.61 Million Stock Holdings in Pinterest, Inc. $PINS
In the latest trading session, Pacific Biosciences of California (PACB - Free Report) closed at $1.36, marking a -5.56% move from the previous day. This change lagged the S&P 500's daily loss of 0.19%. Meanwhile, the Dow experienced a drop of 0.59%, and the technology-dominated Nasdaq saw a decrease of 0.05%.
Heading into today, shares of the maker of genetic analysis technology had gained 2.86% over the past month, lagging the Medical sector's gain of 6.06% and outpacing the S&P 500's gain of 0.55%.
Analysts and investors alike will be keeping a close eye on the performance of Pacific Biosciences of California in its upcoming earnings disclosure. The company's earnings report is set to go public on August 5, 2026. It is anticipated that the company will report an EPS of -$0.14, marking a 7.69% fall compared to the same quarter of the previous year. Alongside, our most recent consensus estimate is anticipating revenue of $40.7 million, indicating a 2.34% upward movement from the same quarter last year.
For the entire fiscal year, the Zacks Consensus Estimates are projecting earnings of -$0.41 per share and a revenue of $165.8 million, representing changes of +22.64% and +3.62%, respectively, from the prior year.
Any recent changes to analyst estimates for Pacific Biosciences of California should also be noted by investors. These revisions help to show the ever-changing nature of near-term business trends. Therefore, positive revisions in estimates convey analysts' confidence in the business performance and profit potential.
Our research suggests that these changes in estimates have a direct relationship with upcoming stock price performance. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Within the past 30 days, our consensus EPS projection remained stagnant. At present, Pacific Biosciences of California boasts a Zacks Rank of #3 (Hold).
The Medical - Instruments industry is part of the Medical sector. This group has a Zacks Industry Rank of 175, putting it in the bottom 29% of all 250+ industries.
The Zacks Industry Rank assesses the vigor of our specific industry groups by computing the average Zacks Rank of the individual stocks incorporated in the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Ensure to harness Zacks.com to stay updated with all these stock-shifting metrics, among others, in the next trading sessions.
MENLO PARK, Calif., July 15, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) announced today that it will hold its quarterly conference call to discuss its second quarter 2026 financial results on Wednesday, August 5, 2026, at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time).
The call will be webcast and may be accessed on PacBio’s website at https://investor.pacificbiosciences.com/.
Date: Wednesday, August 5, 2026, at 4:30 p.m. ET (1:30 p.m. PT)
Listen live via internet or replay: https://investor.pacificbiosciences.com/
Toll-free: 1-888-349-0136
International: 1-412-317-0459
About PacBio
PacBio (NASDAQ: PACB) is a premier life science technology company that designs, develops, and manufactures advanced sequencing solutions to help scientists and clinical researchers resolve genetically complex problems. Our products and technologies, which include our HiFi long-read sequencing, address solutions across a broad set of research applications including human germline sequencing, plant and animal sciences, infectious disease and microbiology, oncology, and other emerging applications. For more information, please visit www.pacb.com and follow @PacBio.
PacBio products are provided for Research Use Only. Not for use in diagnostic procedures.
Pacific Biosciences of California (PACB - Free Report) closed the most recent trading day at $1.49, moving -4.49% from the previous trading session. The stock's change was less than the S&P 500's daily loss of 0.79%. On the other hand, the Dow registered a loss of 0.26%, and the technology-centric Nasdaq decreased by 1.55%.
Heading into today, shares of the maker of genetic analysis technology had gained 19.08% over the past month, outpacing the Medical sector's gain of 5.5% and the S&P 500's gain of 4.28%.
Investors will be eagerly watching for the performance of Pacific Biosciences of California in its upcoming earnings disclosure. It is anticipated that the company will report an EPS of -$0.14, marking a 7.69% fall compared to the same quarter of the previous year. Our most recent consensus estimate is calling for quarterly revenue of $42.1 million, up 5.86% from the year-ago period.
Regarding the entire year, the Zacks Consensus Estimates forecast earnings of -$0.41 per share and revenue of $165.8 million, indicating changes of +22.64% and +3.62%, respectively, compared to the previous year.
Any recent changes to analyst estimates for Pacific Biosciences of California should also be noted by investors. Recent revisions tend to reflect the latest near-term business trends. As such, positive estimate revisions reflect analyst optimism about the business and profitability.
Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. To take advantage of this, we've established the Zacks Rank, an exclusive model that considers these estimated changes and delivers an operational rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has witnessed an unchanged state. Pacific Biosciences of California is holding a Zacks Rank of #2 (Buy) right now.
The Medical - Instruments industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 161, which puts it in the bottom 35% of all 250+ industries.
The Zacks Industry Rank is ordered from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Don't forget to use Zacks.com to keep track of all these stock-moving metrics, and others, in the upcoming trading sessions.
Key Takeaways PacBio gains from product development and a Q1 earnings beat despite funding challenges.PACB's SPRQ-Nx chemistry boosts yields and targets sub-$300 genome sequencing at scale.PacBio sees research funding uncertainty weighing on Revio and Vega demand through 2026. Pacific Biosciences of California, Inc. (PACB - Free Report) , popularly known as PacBio, has been gaining from its continued product development. The optimism, led by strong first-quarter results, is expected to contribute further. However, concerns about funding headwinds persist.
In the year-to-date period, this Zacks Rank #2 (Buy) company’s shares have lost 11.2% compared with the 12.4% decline of the industry. The S&P 500 Composite has improved 9.4% in the said time frame.
The renowned global provider of sequencing systems has a market capitalization of $521.8 million. The company projects 22.6% growth for 2026 and expects to maintain its strong performance in the future. PacBio’s earnings surpassed the Zacks Consensus Estimate in all the trailing four quarters, delivering an average surprise of 29.8%.
Image Source: Zacks Investment Research
Factors Favoring PACB’s GrowthSequencing Technologies Strengthen Market Leadership: PacBio differentiates itself in the genomics industry through its proprietary HiFi long-read sequencing, based on Single-Molecule Real-Time (SMRT) technology. This technology enables the high-accuracy, real-time detection of complex genomic structures, such as structural variations, haplotypes and epigenetic modifications.
Per a report by Data Bridge Market Research, the global SMRT market size was valued at $2.88 billion in 2024 and is projected to reach $4.36 billion by 2032, at a CAGR of 5.3%. Additionally, PacBio has expanded its offerings by integrating Sequencing by Binding chemistry with the launch of its Onso system in 2022, a short-read platform delivering ≥90% of bases at Q40+ accuracy, 15 times more precise than traditional sequencing methods. By providing both long-read and short-read technologies, PacBio uniquely serves diverse research and clinical applications while driving down costs and enhancing variant detection.
Robust Product Portfolio Driving Growth: PacBio continues to strengthen its competitive position through innovation in its HiFi sequencing platform. The company's SPRQ-Nx chemistry is gaining traction, delivering higher sequencing yields and enabling human whole-genome sequencing costs below $300 at scale through reusable SMRT Cells. Management plans to extend the technology to the Vega platform later this year, enhancing throughput and workflow efficiency.
PacBio is also advancing its next-generation ultra-high-throughput sequencing platform to target large-scale clinical and population genomics opportunities. Additionally, its collaboration with Basecamp Research to sequence roughly 100,000 metagenomic samples highlights the expanding role of HiFi sequencing in AI-driven biological research and underscores the technology's growing adoption across emerging applications.
Strong Q1 Results: PacBio exited the first quarter of 2026 with mixed results, wherein earnings beat the Zacks Consensus Estimate while revenues missed the same. Stable top-line performance, despite softer instrument sales, reflected continued strength in consumables demand and improving utilization trends across the installed base.
Growth in consumables revenues, expansion across the EMEA region and disciplined expense management were encouraging. The company also reported a significantly narrower operating loss year over year, supported by lower operating expenses and continued restructuring benefits.
A Factor That May Offset PACB’s GainsFunding Headwinds Continue to Weigh on Instrument Demand: PacBio continues to face funding-related headwinds that are weighing on instrument demand, particularly across academic and government research markets. Uncertainty around grant funding and cautious capital spending have pressured purchases of both Revio and Vega systems, with Vega being more exposed to academic budget constraints.
While the company is seeing growing interest from clinical and commercial customers, management does not anticipate a meaningful recovery in research funding through 2026 and recently lowered the high end of its annual revenue outlook due in part to weaker instrument demand. Although the upcoming commercial launch of SPRQ-Nx chemistry could improve the attractiveness of PacBio’s sequencing platforms by lowering costs and boosting throughput, near-term instrument growth is expected to remain dependent on expanding clinical adoption rather than a broad recovery in research spending.
Estimate TrendPacBio has been witnessing a stable estimate revision trend for 2026. Over the past 30 days, the Zacks Consensus Estimate for its adjusted loss per share has remained stable at 41 cents.
The Zacks Consensus Estimate for 2026 revenues is pegged at $165.8 million, indicating a 3.6% increase from the year-ago reported numbers.
Other Key PicksSome other top-ranked stocks from the broader medical space are Globus Medical (GMED - Free Report) , West Pharmaceutical (WST - Free Report) and Intuitive Surgical (ISRG - Free Report) .
Globus Medical, currently carrying a Zacks Rank #2, reported a first-quarter 2026 adjusted earnings per share (EPS) of $1.12 per share, which surpassed the Zacks Consensus Estimate by 22.1%. Revenues of $759.9 million beat the Zacks Consensus Estimate by 4.0%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
GMED has an estimated long-term earnings growth rate of 10.2% compared with the industry’s 12.6% growth. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 26.3%.
West Pharmaceutical, currently carrying a Zacks Rank #2, reported first-quarter 2026 EPS of $2.13, which beat the Zacks Consensus Estimate by 26.8%. Revenues of $844.9 million surpassed the Zacks Consensus Estimate by 8.5%.
WST has an estimated long-term earnings growth rate of 13.9% compared with the industry’s 9.5% growth. The company’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 19.4%.
Intuitive Surgical, carrying a Zacks Rank #2 at present, reported first-quarter 2026 adjusted EPS of $2.50, which beat the Zacks Consensus Estimate by 20.2%. Revenues of $2.77 billion surpassed the Zacks Consensus Estimate by 6.2%.
ISRG has a long-term estimated growth rate of 14.6% compared with the industry’s 12.6% growth. The company’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 16.8%.
Pacific Biosciences of California (PACB - Free Report) ended the recent trading session at $1.66, demonstrating a -1.19% change from the preceding day's closing price. The stock's change was less than the S&P 500's daily gain of 0.72%. Meanwhile, the Dow experienced a rise of 0.3%, and the technology-dominated Nasdaq saw an increase of 1.12%.
Shares of the maker of genetic analysis technology have appreciated by 15.86% over the course of the past month, outperforming the Medical sector's gain of 12.48%, and the S&P 500's loss of 0.9%.
The upcoming earnings release of Pacific Biosciences of California will be of great interest to investors. It is anticipated that the company will report an EPS of -$0.14, marking a 7.69% fall compared to the same quarter of the previous year. Meanwhile, the latest consensus estimate predicts the revenue to be $42.1 million, indicating a 5.86% increase compared to the same quarter of the previous year.
PACB's full-year Zacks Consensus Estimates are calling for earnings of -$0.41 per share and revenue of $165.8 million. These results would represent year-over-year changes of +22.64% and +3.62%, respectively.
Any recent changes to analyst estimates for Pacific Biosciences of California should also be noted by investors. Such recent modifications usually signify the changing landscape of near-term business trends. Therefore, positive revisions in estimates convey analysts' confidence in the business performance and profit potential.
Based on our research, we believe these estimate revisions are directly related to near-term stock moves. To take advantage of this, we've established the Zacks Rank, an exclusive model that considers these estimated changes and delivers an operational rating system.
The Zacks Rank system, running from #1 (Strong Buy) to #5 (Strong Sell), holds an admirable track record of superior performance, independently audited, with #1 stocks contributing an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has remained unchanged. Pacific Biosciences of California is holding a Zacks Rank of #2 (Buy) right now.
The Medical - Instruments industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 159, which puts it in the bottom 36% of all 250+ industries.
The Zacks Industry Rank assesses the strength of our separate industry groups by calculating the average Zacks Rank of the individual stocks contained within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.
In the latest close session, Pacific Biosciences of California (PACB - Free Report) was down 2.89% at $1.68. The stock fell short of the S&P 500, which registered a gain of 0.79% for the day. Meanwhile, the Dow gained 0.26%, and the Nasdaq, a tech-heavy index, added 1.52%.
Heading into today, shares of the maker of genetic analysis technology had gained 9.49% over the past month, outpacing the Medical sector's gain of 7.53% and the S&P 500's loss of 1.82%.
Market participants will be closely following the financial results of Pacific Biosciences of California in its upcoming release. The company is expected to report EPS of -$0.14, down 7.69% from the prior-year quarter. At the same time, our most recent consensus estimate is projecting a revenue of $42.1 million, reflecting a 5.86% rise from the equivalent quarter last year.
For the full year, the Zacks Consensus Estimates are projecting earnings of -$0.41 per share and revenue of $165.8 million, which would represent changes of +22.64% and +3.62%, respectively, from the prior year.
Any recent changes to analyst estimates for Pacific Biosciences of California should also be noted by investors. These revisions typically reflect the latest short-term business trends, which can change frequently. As a result, upbeat changes in estimates indicate analysts' favorable outlook on the business health and profitability.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system.
The Zacks Rank system, running from #1 (Strong Buy) to #5 (Strong Sell), holds an admirable track record of superior performance, independently audited, with #1 stocks contributing an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has remained unchanged. Pacific Biosciences of California presently features a Zacks Rank of #2 (Buy).
The Medical - Instruments industry is part of the Medical sector. At present, this industry carries a Zacks Industry Rank of 164, placing it within the bottom 33% of over 250 industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Keep in mind to rely on Zacks.com to watch all these stock-impacting metrics, and more, in the succeeding trading sessions.
Pacific Biosciences of California (PACB - Free Report) ended the recent trading session at $1.31, demonstrating a -2.96% change from the preceding day's closing price. The stock fell short of the S&P 500, which registered a gain of 0.5% for the day. Meanwhile, the Dow experienced a rise of 0.7%, and the technology-dominated Nasdaq saw an increase of 0.31%.
Coming into today, shares of the maker of genetic analysis technology had gained 11.57% in the past month. In that same time, the Medical sector gained 5.49%, while the S&P 500 lost 0.23%.
The investment community will be paying close attention to the earnings performance of Pacific Biosciences of California in its upcoming release. The company is predicted to post an EPS of -$0.14, indicating a 7.69% decline compared to the equivalent quarter last year. Simultaneously, our latest consensus estimate expects the revenue to be $42.1 million, showing a 5.86% escalation compared to the year-ago quarter.
PACB's full-year Zacks Consensus Estimates are calling for earnings of -$0.41 per share and revenue of $165.8 million. These results would represent year-over-year changes of +22.64% and +3.62%, respectively.
It's also important for investors to be aware of any recent modifications to analyst estimates for Pacific Biosciences of California. These revisions help to show the ever-changing nature of near-term business trends. Hence, positive alterations in estimates signify analyst optimism regarding the business and profitability.
Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system, spanning from #1 (Strong Buy) to #5 (Strong Sell), boasts an impressive track record of outperformance, audited externally, with #1 ranked stocks yielding an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 7.41% higher. Pacific Biosciences of California currently has a Zacks Rank of #2 (Buy).
The Medical - Instruments industry is part of the Medical sector. This industry, currently bearing a Zacks Industry Rank of 149, finds itself in the bottom 39% echelons of all 250+ industries.
The Zacks Industry Rank is ordered from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to use Zacks.com to monitor all these stock-influencing metrics, and more, throughout the forthcoming trading sessions.
MENLO PARK, Calif., April 16, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) announced today that it will hold its quarterly conference call to discuss its first quarter 2026 financial results on Thursday, May 7, 2026, at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time).
The call will be webcast and may be accessed on PacBio’s website at https://investor.pacificbiosciences.com/.
Date: Thursday, May 7, 2026, at 4:30 p.m. ET (1:30 p.m. PT)
Listen live via internet or replay: https://investor.pacificbiosciences.com/
Toll-free: 1-888-349-0136
International: 1-412-317-0459
About PacBio
PacBio (NASDAQ: PACB) is a premier life science technology company that designs, develops, and manufactures advanced sequencing solutions to help scientists and clinical researchers resolve genetically complex problems. Our products and technologies, which include our HiFi long-read sequencing, address solutions across a broad set of research applications including human germline sequencing, plant and animal sciences, infectious disease and microbiology, oncology, and other emerging applications. For more information, please visit www.pacb.com and follow @PacBio.
PacBio products are provided for Research Use Only. Not for use in diagnostic procedures.
Key Takeaways PACB launched a joint FFPE workflow with Covaris to improve the sequencing of archived tumor samples.The solution enhances DNA recovery, boosting structural variant detection and mutation phasing accuracy.PACB sees growth potential as workflow expands use of HiFi sequencing in research and clinical settings. PacBio (PACB - Free Report) recently announced a new joint workflow with Covaris, a PerkinElmer company and leader in sample preparation technologies, aimed at enabling highly accurate HiFi long-read sequencing from formalin-fixed, paraffin-embedded (FFPE) tumor samples. The integrated solution combines Covaris’ advanced extraction technology with PacBio’s library preparation and Revio sequencing system, helping overcome long-standing challenges related to DNA damage and fragmentation in archived clinical samples.
The development significantly expands the usability of FFPE samples, which are widely available and critical for cancer research. By delivering higher-quality sequencing data, improved structural variant detection and direct mutation phasing, the workflow positions PacBio to unlock valuable insights from previously underutilized tumor archives and strengthen its role in advancing oncology research.
Likely Trend of PACB Stock Following the NewsShares of PACB have gained 1.9% since the announcement on Thursday. In the year-to-date period, shares of the company lost 12.8% compared with the industry’s 11.4% decline. The S&P 500 increased 2.8% in the same time frame.
This joint workflow is likely to strengthen PacBio’s long-term growth by expanding the addressable market for its HiFi sequencing platforms, particularly into the vast backlog of FFPE clinical samples that were previously difficult to analyze. By enabling high-quality long-read sequencing from these archived tissues, PacBio can drive higher adoption of its Revio system in both research and clinical settings, increasing instrument utilization and recurring consumables revenue.
PACB currently has a market capitalization of $483.2 million.
Image Source: Zacks Investment Research
More on the NewsA key highlight of the joint workflow is its ability to recover longer DNA fragments, up to 5,000 base pairs, from heavily degraded FFPE samples using Covaris’ Adaptive Focused Acoustics-based truXTRAC extraction technology. These fragments are then processed through PacBio’s Kinnex library preparation, which concatenates shorter DNA pieces into longer molecules optimized for HiFi sequencing on the Revio system. This integrated approach not only improves sequencing efficiency but also ensures higher data quality, addressing a major limitation that has historically restricted the use of FFPE samples in long-read sequencing.
Importantly, performance data underscores the workflow’s potential impact. Across multiple tumor types, including brain, kidney and uterine samples, the solution generated more than 100 million HiFi reads per sample, with mean read lengths ranging from 750 to 1,500 base pairs. This enabled detection of more than 11,000 structural variants and over 5 million small variants per sample, with roughly 60% of variants directly phased into haplotypes. Compared to traditional short-read sequencing, which typically identifies fewer structural variants and relies on indirect phasing methods, this workflow delivers deeper and more actionable genomic insights, making it particularly valuable for complex cancer research applications.
Favorable Industry Prospect for PACBPer a report by Grand View Research, the global long-read sequencing market size was estimated at $538.9 million in 2024 and is projected to reach $1.53 billion by 2030, expanding at a CAGR of 20.12% from 2025 to 2030.
The major factors driving market growth include the increasing prevalence of genetic diseases like cancers and chromosomal disorders.
Recent Developments by PACBIn March, PACB announced that Basecamp Research has selected its HiFi sequencing technology on the Revio system to support the ambitious Trillion Gene Atlas initiative.
The collaboration highlights the growing importance of high-accuracy, long-read sequencing in powering next-generation AI-driven drug discovery. By preserving full genomic context, PacBio’s HiFi sequencing is expected to enable more precise biological insights and improve the training of foundation models like Basecamp’s EDEN platform, ultimately accelerating the design of novel therapeutics at scale.
PACB’s Zacks Rank & Other Key PicksCurrently, PACB sports a Zacks Rank #1 (Strong Buy).
Some other top-ranked stocks from the broader medical space are Phibro Animal Health (PAHC - Free Report) , GE HealthCare Technologies (GEHC - Free Report) and Cardinal Health (CAH - Free Report) .
Phibro Animal Health, currently sporting a Zacks Rank #1, reported second-quarter fiscal 2026 adjusted earnings per share (EPS) of 87 cents, which surpassed the Zacks Consensus Estimate by 27.1%. Revenues of $373.9 million beat the Zacks Consensus Estimate by 4.7%. You can see the complete list of today’s Zacks #1 Rank stocks here.
PAHC has an estimated long-term earnings growth rate of 21.5% compared with the industry’s 12% rise. The company’s earnings beat estimates in the trailing four quarters, the average surprise being 20.1%.
GE HealthCare Technologies, currently carrying a Zacks Rank #2 (Buy), reported fourth-quarter 2025 adjusted EPS of $1.44, which surpassed the Zacks Consensus Estimate by 0.7%. Revenues of $5.7 billion beat the Zacks Consensus Estimate by 1.9%.
GEHC has an estimated long-term earnings growth rate of 9.1% compared with the industry’s 12% rise. The company beat earnings estimates in the trailing four quarters, the average surprise being 7.5%.
Cardinal Health, currently carrying a Zacks Rank #2, reported a second-quarter fiscal 2026 adjusted EPS of $2.63, which surpassed the Zacks Consensus Estimate by 10%. Revenues of $65.6 billion beat the Zacks Consensus Estimate by 0.9%.
CAH has an estimated long-term earnings growth rate of 15% compared with the industry’s 9.3% rise. The company’s earnings beat estimates in the trailing four quarters, the average surprise being 9.3%.
Expands access to streamlined genomic data analysis across the PacBio partner ecosystem April 21, 2026 09:05 ET | Source: PacBio
MENLO PARK, Calif. & BERLIN, April 21, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a premier developer of sequencing solutions, and Lucid Genomics GmbH, a provider of cutting-edge bioinformatics software for clinical and research genomics, today announced that Lucid Genomics has joined the PacBio Compatible partner program as a solution for tertiary analysis of data generated on PacBio long-read sequencing instruments.
Tertiary analysis represents a critical step in the sequencing workflow, where processed genomic data is translated into biological and potentially clinically relevant insights. Tertiary analysis enables streamlined annotation, interpretation, and reporting of genomic variants to help derive value from sequencing data and better understand variation underlying human disease.
This collaboration highlights the interoperability of Lucid Genomics’ analysis platform with PacBio’s HiFi sequencing technology, enabling scientists and clinical researchers to transform long-read sequencing data into meaningful genomic insights. From variant calling and structural variant detection to comprehensive clinical interpretation, Lucid Genomics delivers a unified workflow optimized for the accuracy and throughput of HiFi sequencing. This collaboration helps laboratories move more efficiently from sequencing to actionable insights.
Compatibility Built on Performance and Precision
PacBio’s Compatible partner program recognizes third-party providers whose solutions have been evaluated to work seamlessly with PacBio instruments and data formats. As a named partner, Lucid Genomics joins a growing ecosystem of organizations supporting high-quality downstream analysis of PacBio long-read sequencing data.
Lucid Genomics’ platform supports a broad range of analysis tasks, including alignment, phasing, variant annotation, methylation analysis, and visualization, all purpose-built to leverage the high fidelity and long-range information unique to PacBio HiFi reads. The integration enables laboratories of all sizes to adopt a streamlined, validated pipeline from sequencer to clinical or research report.
“Being recognized as a PacBio Compatible partner is a significant milestone for Lucid Genomics and for our customers. Long-read sequencing is unlocking parts of the genome that were simply invisible before: non-coding regions, methylation patterns, structural variants in the dark genome,” said Dr. Uira Souto Melo, Founder & CEO, Lucid Genomics. “Lucid was built from the ground up as a long-read native company to extract exactly this kind of diagnostic value. This designation gives our users confidence they are working with a solution that is tested, trusted, and purpose-fit for PacBio sequencing.”
“PacBio is committed to building a strong ecosystem of compatible solutions that enable our customers to fully realize the value of HiFi sequencing across the entire workflow,” said Dave Miller, Vice President of Global Marketing, PacBio. “Lucid Genomics brings a powerful, long-read-native approach to tertiary analysis, and we’re pleased to expand the range of compatible tools available to our customers to better derive biological insights from HiFi sequencing data.”
Expanded Access to Validated Long-Read Workflows
For laboratories and research institutions using PacBio systems, this collaboration is intended to provide a clear path to scalable, production-ready tertiary analysis. Users can access Lucid Genomics’ cloud-native platform with confidence that workflows have been designed and assessed for compatibility with PacBio data standards and leverage computation tools developed specifically for HiFi sequencing, helping to reduce integration risk and accelerate time to insight.
PacBio and Lucid Genomics may collaborate on joint customer engagements, technical enablement resources, and co-marketing initiatives to support the growing global community of HiFi sequencing users.
For more information, visit www.pacb.com or www.lucid-genomics.com.
About PacBio
PacBio (NASDAQ: PACB) is a premier life science technology company that designs, develops, and manufactures advanced sequencing solutions to help scientists and clinical researchers resolve genetically complex problems. Our products and technologies, including HiFi long-read sequencing, support a broad range of applications, including human germline sequencing, plant and animal sciences, infectious disease and microbiology, oncology, and other emerging areas. For more information, visit www.pacb.com.
PacBio products are provided for Research Use Only. Not for use in diagnostic procedures.
About Lucid Genomics
Lucid Genomics is a bioinformatics company dedicated to making genomic data analysis faster, more accurate, and more accessible. The company’s cloud-native platform supports secondary and tertiary analysis for clinical laboratories, research institutions, and biotechnology companies working with next-generation and long-read sequencing technologies.
Forward-Looking Statements
This press release may contain “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and the U.S. Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact are forward-looking statements, including statements relating to the availability, uses, accuracy, advantages, quality or performance of, or benefits of using, or expected benefits of using, PacBio products or technologies, including in connection with Lucid Genomics joining the PacBio Compatible Program and the collaboration between the companies to advance tertiary analysis for long-read sequencing using Lucid Technologies’ platform; transforming long-read sequencing data into meaningful genomic insights; moving more efficiently from sequencing to actionable insights; enabling laboratories to adopt a streamlined, validated pipeline from sequencer to clinical or research report; enabling customers to fully realize the value of HiFi sequencing across the workflow; allowing customers to better derive biological insights from HiFi sequencing data; and other future events. You should not place undue reliance on forward-looking statements because they are subject to assumptions, risks, and uncertainties and could cause actual outcomes and results to differ materially from currently anticipated results, including, challenges inherent in using new technologies; potential product performance and quality issues; rapidly changing technologies and extensive competition in, and potential FDA regulatory issues relating to, genomic sequencing; unanticipated increases in costs or expenses; interruptions or delays in the supply of components or materials for, or manufacturing of, PacBio products and products under development; third-party claims alleging infringement of patents and proprietary rights or seeking to invalidate PacBio's patents or proprietary rights, among others. Additional factors that could materially affect actual results can be found in PacBio's most recent filings with the Securities and Exchange Commission, including PacBio's most recent reports on Forms 8-K, 10-K, and 10-Q, and include those listed under the caption "Risk Factors." These forward-looking statements are based on current expectations and speak only as of the date hereof; except as required by law, PacBio disclaims any obligation to revise or update these forward-looking statements to reflect events or circumstances in the future, even if new information becomes available.
Key Takeaways PACB partners with Lucid Genomics to enhance tertiary analysis for HiFi sequencing workflows.PACB integrates Lucid's platform to streamline variant detection, interpretation and reporting.PacBio aims to reduce workflow complexity and accelerate insights, supporting broader adoption. PacBio (PACB - Free Report) recently announced a compatibility collaboration with Lucid Genomics, bringing the latter into its Compatible partner program to strengthen tertiary analysis capabilities for long-read sequencing. The move expands PacBio’s ecosystem by enabling seamless integration of Lucid’s bioinformatics platform with its HiFi sequencing technology, helping users translate raw sequencing data into meaningful biological and clinical insights more efficiently.
The partnership is aimed at simplifying downstream analysis workflows, covering everything from variant detection and annotation to interpretation and reporting. By offering a validated, end-to-end pipeline optimized for HiFi data, the collaboration is expected to reduce integration complexity for labs and accelerate time to actionable insights, supporting broader adoption of PacBio’s long-read sequencing solutions across research and clinical settings.
Likely Trend of PACB Stock Following the NewsShares of PACB have gained 1.9% in yesterday’s after-market trading since the announcement. In the year-to-date period, shares of the company lost 7.5% compared with the industry’s 11.1% decline. The S&P 500 increased 4% in the same time frame.
This collaboration strengthens PacBio’s long-term business by deepening its ecosystem and making its HiFi sequencing platform more user-friendly. By integrating a validated tertiary analysis solution, PacBio reduces a key friction point in the workflow, making it easier for labs to move from sequencing to actionable insights. This improves customer retention, attracts new users, especially in clinical and translational research and enhances the overall value proposition of its systems.
PACB currently has a market capitalization of $525.5 million.
Image Source: Zacks Investment Research
More on the NewsTertiary analysis represents a critical step in the sequencing workflow, where processed genomic data is translated into biological and clinically relevant insights. It enables streamlined annotation, interpretation and reporting of genomic variants, helping researchers derive real value from sequencing data and better understand the genetic basis of disease. In this context, the collaboration underscores the interoperability of Lucid Genomics’ platform with PacBio’s HiFi sequencing, allowing users to convert long-read data into actionable insights more efficiently. From variant calling and structural variant detection to comprehensive clinical interpretation, Lucid offers a unified workflow optimized for the accuracy and throughput of HiFi reads.
PacBio’s Compatible partner program plays a central role in this integration by validating third-party solutions that work seamlessly with its instruments and data formats. With Lucid Genomics now part of this ecosystem, customers gain access to a robust set of downstream analysis tools tailored for long-read sequencing. The platform supports a wide range of functionalities, including alignment, phasing, variant annotation, methylation analysis and visualization—all designed to fully leverage the depth and precision of HiFi sequencing. This enables labs to adopt a streamlined, end-to-end pipeline that connects sequencing output directly to research or clinical reporting.
Another important aspect is the focus on scalability and ease of adoption. Lucid Genomics’ cloud-native platform offers a production-ready solution that reduces integration challenges while ensuring compatibility with PacBio data standards. This lowers technical barriers for labs of different sizes and accelerates time to insight. Additionally, both companies plan to collaborate on joint customer engagements, technical enablement and co-marketing initiatives, which should help expand the global footprint of HiFi sequencing and further strengthen PacBio’s partner-driven ecosystem strategy.
Favorable Industry Prospect for PACBPer a report by Grand View Research, the global long-read sequencing market size was estimated at $538.9 million in 2024 and is projected to reach $1.53 billion by 2030, expanding at a CAGR of 20.12% from 2025 to 2030.
The major factors driving market growth include the increasing prevalence of genetic diseases like cancers and chromosomal disorders.
A Recent Development by PACBIn March, PACB announced that Basecamp Research has selected its HiFi sequencing technology on the Revio system to support the ambitious Trillion Gene Atlas initiative.
The collaboration highlights the growing importance of high-accuracy, long-read sequencing in powering next-generation AI-driven drug discovery. By preserving full genomic context, PacBio’s HiFi sequencing is expected to enable more precise biological insights and improve the training of foundation models like Basecamp’s EDEN platform, ultimately accelerating the design of novel therapeutics at scale.
Some better-ranked stocks from the broader medical space are Phibro Animal Health (PAHC - Free Report) , GE HealthCare Technologies (GEHC - Free Report) and Cardinal Health (CAH - Free Report) .
Phibro Animal Health, currently sporting a Zacks Rank #1 (Strong Buy), reported second-quarter fiscal 2026 adjusted earnings per share (EPS) of 87 cents, which surpassed the Zacks Consensus Estimate by 27.1%. Revenues of $373.9 million beat the Zacks Consensus Estimate by 4.7%. You can see the complete list of today’s Zacks #1 Rank stocks here.
PAHC has an estimated long-term earnings growth rate of 21.5% compared with the industry’s 12% rise. The company’s earnings beat estimates in the trailing four quarters, the average surprise being 20.1%.
GE HealthCare Technologies, currently carrying a Zacks Rank #2 (Buy), reported fourth-quarter 2025 adjusted EPS of $1.44, which surpassed the Zacks Consensus Estimate by 0.7%. Revenues of $5.7 billion beat the Zacks Consensus Estimate by 1.9%.
GEHC has an estimated long-term earnings growth rate of 9.1% compared with the industry’s 12% rise. The company beat earnings estimates in the trailing four quarters, the average surprise being 7.5%.
Cardinal Health, currently carrying a Zacks Rank #2, reported a second-quarter fiscal 2026 adjusted EPS of $2.63, which surpassed the Zacks Consensus Estimate by 10%. Revenues of $65.6 billion beat the Zacks Consensus Estimate by 0.9%.
CAH has an estimated long-term earnings growth rate of 15% compared with the industry’s 9.3% rise. The company’s earnings beat estimates in the trailing four quarters, the average surprise being 9.3%.
Pacific Biosciences of California (PACB - Free Report) ended the recent trading session at $1.71, demonstrating a -1.16% change from the preceding day's closing price. The stock trailed the S&P 500, which registered a daily gain of 1.05%. Meanwhile, the Dow experienced a rise of 0.69%, and the technology-dominated Nasdaq saw an increase of 1.64%.
Shares of the maker of genetic analysis technology witnessed a gain of 24.46% over the previous month, beating the performance of the Medical sector with its gain of 0.31%, and the S&P 500's gain of 8.59%.
Investors will be eagerly watching for the performance of Pacific Biosciences of California in its upcoming earnings disclosure. The company's earnings report is set to be unveiled on May 7, 2026. The company's upcoming EPS is projected at -$0.17, signifying a 13.33% drop compared to the same quarter of the previous year. In the meantime, our current consensus estimate forecasts the revenue to be $41 million, indicating a 10.36% growth compared to the corresponding quarter of the prior year.
Looking at the full year, the Zacks Consensus Estimates suggest analysts are expecting earnings of -$0.54 per share and revenue of $175.4 million. These totals would mark changes of -1.89% and +9.62%, respectively, from last year.
Any recent changes to analyst estimates for Pacific Biosciences of California should also be noted by investors. These latest adjustments often mirror the shifting dynamics of short-term business patterns. Therefore, positive revisions in estimates convey analysts' confidence in the business performance and profit potential.
Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system, ranging from #1 (Strong Buy) to #5 (Strong Sell), possesses a remarkable history of outdoing, externally audited, with #1 stocks returning an average annual gain of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has remained unchanged. Pacific Biosciences of California currently has a Zacks Rank of #3 (Hold).
The Medical - Instruments industry is part of the Medical sector. At present, this industry carries a Zacks Industry Rank of 90, placing it within the top 37% of over 250 industries.
The Zacks Industry Rank assesses the strength of our separate industry groups by calculating the average Zacks Rank of the individual stocks contained within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Remember to apply Zacks.com to follow these and more stock-moving metrics during the upcoming trading sessions.
Autonomix Medical (NASDAQ:AMIX – Get Free Report) and Pacific Biosciences of California (NASDAQ:PACB – Get Free Report) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, institutional ownership, analyst recommendations, dividends, risk, earnings and valuation.
Profitability This table compares Autonomix Medical and Pacific Biosciences of California’s net margins, return on equity and return on assets.
Net Margins Return on Equity Return on Assets Autonomix Medical N/A -228.82% -186.65% Pacific Biosciences of California -341.47% -326.43% -19.40% Analyst Ratings This is a summary of recent recommendations and price targets for Autonomix Medical and Pacific Biosciences of California, as reported by MarketBeat.com.
Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Autonomix Medical 1 1 1 0 2.00 Pacific Biosciences of California 2 2 1 0 1.80 Autonomix Medical presently has a consensus price target of $2.00, suggesting a potential upside of 442.89%. Pacific Biosciences of California has a consensus price target of $1.67, suggesting a potential upside of 6.84%. Given Autonomix Medical’s stronger consensus rating and higher possible upside, research analysts plainly believe Autonomix Medical is more favorable than Pacific Biosciences of California.
Volatility & Risk Autonomix Medical has a beta of -2.48, indicating that its share price is 348% less volatile than the S&P 500. Comparatively, Pacific Biosciences of California has a beta of 2.33, indicating that its share price is 133% more volatile than the S&P 500.
Insider & Institutional Ownership 10.8% of Autonomix Medical shares are held by institutional investors. 6.2% of Autonomix Medical shares are held by insiders. Comparatively, 2.4% of Pacific Biosciences of California shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Valuation & Earnings This table compares Autonomix Medical and Pacific Biosciences of California”s top-line revenue, earnings per share (EPS) and valuation.
Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Autonomix Medical N/A N/A -$11.41 million ($3.55) -0.10 Pacific Biosciences of California $160.01 million 3.03 -$546.38 million ($1.84) -0.85 Autonomix Medical has higher earnings, but lower revenue than Pacific Biosciences of California. Pacific Biosciences of California is trading at a lower price-to-earnings ratio than Autonomix Medical, indicating that it is currently the more affordable of the two stocks.
Summary Autonomix Medical beats Pacific Biosciences of California on 8 of the 12 factors compared between the two stocks.
About Autonomix Medical (Get Free Report)
Autonomix Medical, Inc., a development stage medical device development company, focuses on advancing technologies for sensing and treating disorders relating to the peripheral nervous system. Its technology platform includes a catheter-based microchip-enabled sensing array to detect and differentiate peripheral neural signals. The company was incorporated in 2014 and is based in The Woodlands, Texas.
About Pacific Biosciences of California (Get Free Report)
Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing solution to resolve genetically complex problems. The company provides sequencing systems; consumable products, including single molecule real-time (SMRT) technology; long-red sequencing; and various reagent kits designed for specific workflow, such as preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases. It also offers binding kits, such as modified DNA polymerase used to bind SMRTbell libraries to the polymerase in preparation for sequencing; and sequencing kits comprise reagents required for on-instrument, real-time sequencing, including the phospholinked nucleotides. In addition, it provides revio system + sequel systems which conduct, monitor, and analyze single-molecule biochemical reactions in real time; SBB short-read sequencing; onso instrument conducts, monitors, and analyzes SBB biochemical reactions; and SBB consumable, including flow cells, clustering, and sequencing reagent kits. The company serves academic and governmental research institutions; commercial testing and service laboratories; genome centers; public health labs, hospitals and clinical research institutes, and contract research organizations; pharmaceutical companies; and agricultural companies. It markets its products through a sales force and distribution partners in Asia, Australia, Europe, the Middle East, Africa, and Latin America. It has a development and commercialization agreement with Invitae Corporation; and a collaboration with Radboud University Medical to explore genetic causes of rare and genetic diseases. The company was formerly known as Nanofluidics, Inc. and changed its name to Pacific Biosciences of California, Inc. in 2005. Pacific Biosciences of California, Inc. was incorporated in 2000 and is headquartered in Menlo Park, California.
Receive News & Ratings for Autonomix Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Autonomix Medical and related companies with MarketBeat.com's FREE daily email newsletter.
« PREVIOUS HEADLINEContrasting LuxUrban Hotels (NASDAQ:LUXH) and Yangtze River Port and Logistics (OTCMKTS:YRIV)
NEXT HEADLINE »Financial Contrast: Molson Coors Beverage (NYSE:TAP) & Brown Forman (NYSE:BF.A)
MENLO PARK, Calif., May 07, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) today announced financial results for the quarter ended March 31, 2026.
Recent Business Highlights
Selected by Basecamp Research to power its Trillion Gene Atlas, which is expected to result in approximately 100,000 samples being deeply sequenced from over 31 countriesAnnounced a collaboration with DNAstack to power the first global federated HiFi whole genome datasetExpanded SPRQ-Nx beta program to more customers domestically and internationally after receiving positive feedback from initial usersEMEA revenue grew by 17% year-over-year as a result of increased consumables demand reflecting both account expansion and higher utilization, particularly in clinical settingsNamed Lucid Genomics as a PacBio Compatible partner for tertiary analysis of data generated on PacBio's long-read sequencing instrumentsCompleted sale of short-read sequencing assets for net cash proceeds of approximately $48.1 million, strengthening the balance sheet and extending cash runway “We continue to see increasing clinical adoption of HiFi which contributed to another record quarter for consumable revenue. However, instrument revenue, particularly Vega, was lower than we had expected," said Christian Henry, President and Chief Executive Officer. "Nonetheless, we made significant progress on several important initiatives, such as our expansion of the SPRQ-Nx beta program based on the positive early feedback on the new chemistry. Based on this success, we plan to execute a broad commercial rollout to all Revio customers later this month, which we believe will further catalyze consumable growth and Revio instrument demand. Additionally, we continue to prove our ability to win large-scale projects as we were selected by Basecamp Research to power the Trillion Gene Atlas, which has the potential to produce the largest and most diverse high-fidelity metagenomic dataset in the world."
First quarter results:
Q12026Q12025Revenue(in millions)$37.2$37.2Consumable revenue(in millions)$21.8$20.1Instrument revenue(in millions)$9.7$11.0Service and other revenue(in millions)$5.6$6.0Revio™system placements1512Vega™system placements2728Annualized Revio pull-through per system~$229,000~$236,000Ending cash, cash equivalents, and investments(in millions)$276.0$343.1 Gross margin, operating expenses, net loss, and net loss per share are reported on a GAAP and non-GAAP basis. The non-GAAP measures are described below and reconciled to the corresponding GAAP measures at the end of this release.
We recorded a GAAP gross profit of $12.8 million during the first quarter of 2026 compared to a GAAP gross loss of $1.4 million during the first quarter of 2025. GAAP gross loss for the first quarter of 2025 reflected charges related to our restructuring announced April 9, 2025 and included $7.7 million in restructuring-related inventory charges, $4.3 million of amortization of acquired intangible assets, and a $4.1 million loss on purchase commitments. Non-GAAP gross profit for the first quarter of 2026 was $13.8 million compared to non-GAAP gross profit of $15.0 million for the first quarter of 2025. GAAP gross margin was 35% for the first quarter of 2026 compared to a negative GAAP gross margin of 4% for the first quarter of 2025. Non-GAAP gross margin was 37% for the first quarter of 2026 compared to a non-GAAP gross margin of 40% for the first quarter of 2025. The decline in Non-GAAP gross margin was primarily driven by increased computing component costs, temporary first quarter promotions for Vega and inventory and warranty-related adjustments and charges.
GAAP operating expenses totaled $21.2 million for the first quarter of 2026, compared to $427.6 million for the first quarter of 2025. GAAP operating expenses for the first quarter of 2026 included $16.3 million of litigation settlement charges and related legal fees, and a gain on disposal of assets of approximately $45.8 million. GAAP operating expenses for the first quarter of 2025 include $381.8 million of charges associated with the Company’s restructuring efforts and re-focus on its long-read business, partially offset by an $18.7 million decrease in the change in the fair value of contingent consideration. Non-GAAP operating expenses totaled $49.9 million for the first quarter of 2026, compared to $61.7 million for the first quarter of 2025. GAAP and non-GAAP operating expenses for the first quarter of 2026 and the first quarter of 2025 included non-cash share-based compensation of $3.8 million and $8.0 million, respectively.
GAAP net loss for the first quarter of 2026 was $8.3 million, compared to $426.1 million for the first quarter of 2025. Non-GAAP net loss for the first quarter of 2026 was $35.9 million, compared to $44.4 million for the first quarter of 2025.
GAAP net loss per share for the first quarter of 2026 was $0.03, compared to $1.44 for the first quarter of 2025. Non-GAAP net loss per share for the first quarter of 2026 was $0.12, compared to $0.15 for the first quarter of 2025.
2026 Financial Outlook
PacBio expects revenue for the full year 2026 to be in the range of $165 million to $175 million.
Quarterly Conference Call Information
Management will host a quarterly conference call today at 4:30 p.m. Eastern Time to review financial results for the first quarter ended March 31, 2026. Investors can access the call by dialing 1-888-349-0136 (or 1-412-317-0459 for international callers) and requesting to join the “PacBio Q1 Earnings Call". The call will be webcast live and available for replay at PacBio's website at https://investor.pacificbiosciences.com.
About PacBio
PacBio (NASDAQ: PACB) is a premier life science technology company that designs, develops, and manufactures advanced sequencing solutions to help scientists and clinical researchers resolve genetically complex problems. Our products and technologies, which primarily consist of our HiFi long-read sequencing systems, address solutions across a broad set of research applications, including human germline sequencing, plant and animal sciences, infectious disease and microbiology, oncology, and other emerging applications. For more information, please visit www.pacb.com and follow @PacBio.
PacBio products are provided for Research Use Only. Not for use in diagnostic procedures.
Statement regarding use of non‐GAAP financial measures
PacBio reports non‐GAAP results for basic net income and loss per share, net income, net loss, gross margins, gross profit (loss) and operating expenses in addition to, and not as a substitute for, or because it believes that such information is superior to, financial measures calculated in accordance with GAAP. PacBio believes that non-GAAP financial information, when taken collectively, may be helpful to investors because it provides consistency and comparability with past financial performance. However, non-GAAP financial information is presented for supplemental informational purposes only, has limitations as an analytical tool and should not be considered in isolation or as a substitute for financial information presented in accordance with GAAP. In addition, other companies may calculate similarly titled non-GAAP measures differently or may use other measures to evaluate their performance, all of which could reduce the usefulness of PacBio’s non-GAAP financial measures as tools for comparison.
PacBio's financial measures under GAAP include substantial charges that are listed in the itemized reconciliations between GAAP and non‐GAAP financial measures included in this press release. PacBio excludes recurring charges from its non-GAAP financial statements, including amortization of acquired intangible assets and changes in fair value of contingent consideration, and further excludes infrequent and limited charges including impairment charges, restructuring-related expenses for discrete restructuring events, settlement charges, disposition of short-read assets, benefits from income taxes and other adjustments and rounding differences.
Management has excluded the effects of these items in non‐GAAP measures to assist investors in analyzing and assessing past and future operating performance. In addition, management uses non-GAAP measures to compare PacBio’s performance relative to forecasts and strategic plans and to benchmark its performance externally against competitors.
PacBio encourages investors to carefully consider its results under GAAP, as well as its supplemental non‐GAAP information and the reconciliation between these presentations, to more fully understand its business. A reconciliation of PacBio’s non-GAAP financial measures to their most directly comparable financial measure stated in accordance with GAAP has been provided in the financial statement tables included in this press release. PacBio is unable to reconcile future-looking non-GAAP guidance without unreasonable effort because certain items that impact this measure are out of PacBio's control and/or cannot be reasonably predicted at this time.
Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and the U.S. Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact are forward-looking statements, including, but not limited to, statements relating to PacBio’s initiatives as well as the expected financial impact and timing of these plans and initiatives, including our expectations regarding SPRQ-Nx; PacBio’s financial guidance and expectations for future periods; new and continued reception of PacBio’s products and their expansion into new or existing markets; our expectations regarding our collaboration with Basecamp Research; developments affecting our industry and the markets in which we compete, including the impact of new products and technologies and tariffs; anticipated results of studies and future customer use and costs of our products and consumables, including the increasing clinical adoption of HiFi; and the availability, uses, accuracy, coverage, advantages, quality or performance of, or benefits or expected benefits of using, PacBio products or technologies. Reported results and orders for any instrument system should not be considered an indication of future performance. You should not place undue reliance on forward-looking statements because they are subject to assumptions, risks, and uncertainties and could cause actual outcomes and results to differ materially from currently anticipated results, including, but not limited to, challenges inherent in developing, manufacturing, launching, marketing and selling new products, and achieving anticipated new sales; potential cancellation of existing instrument orders; assumptions, risks and uncertainties related to the ability to attract new customers and retain and grow sales from existing customers; risks related to PacBio's ability to successfully execute and realize the benefits of acquisitions; the impact of new, increased or enhanced tariffs and export restrictions; rapidly changing technologies and extensive competition in genomic sequencing; unanticipated increases in costs or expenses; high costs of computer memory components; interruptions or delays in the supply of components or materials for, or manufacturing of, PacBio products and products under development; potential product performance and quality issues and potential delays in development timelines; the possible loss of key employees, customers, or suppliers; customers and prospective customers curtailing or suspending activities using PacBio's products; third-party claims alleging infringement of patents and proprietary rights or seeking to invalidate PacBio's patents or proprietary rights; risks associated with international operations; and other risks associated with general macroeconomic conditions and global economic or political instability, including war and other international conflicts, such as the conflicts in the Middle East. Additional factors that could materially affect actual results can be found in PacBio's most recent filings with the Securities and Exchange Commission, including PacBio's most recent reports on Forms 8-K, 10-K, and 10-Q, and include those listed under the caption “Risk Factors.” These forward-looking statements are based on current expectations and speak only as of the date hereof; except as required by law, PacBio disclaims any obligation to revise or update these forward-looking statements to reflect events or circumstances in the future, even if new information becomes available.
The unaudited condensed consolidated financial statements that follow should be read in conjunction with the notes set forth in PacBio's Quarterly Report on Form 10-Q when filed with the Securities and Exchange Commission.
Pacific Biosciences of California, Inc.
Unaudited Condensed Consolidated Statements of Operations
Three Months Ended(in thousands, except per share amounts)March 31,
2026 December 31,
2025 March 31,
2025Revenue: Product revenue$31,534 $38,965 $31,113 Service and other revenue 5,644 5,680 6,040 Total revenue 37,178 44,645 37,153 Cost of Revenue: Cost of product revenue(1)(3)(4) 19,972 24,204 26,333 Cost of service and other revenue 4,182 3,681 3,778 Amortization of acquired intangible assets 183 183 4,345 Loss on purchase commitment(1) — 11 4,068 Total cost of revenue 24,337 28,079 38,524 Gross profit (loss) 12,841 16,566 (1,371)Operating Expense: Research and development(1) 19,608 22,879 29,053 Sales, general and administrative(1)(3) 31,153 34,051 40,168 Impairment charges(2) — — 15,000 Settlement charges(3) 15,400 — — Gain on disposal of assets(4) (45,796) — — Amortization of acquired intangible assets(5) 833 833 362,042 Change in fair value of contingent consideration(6) — — (18,700)Total operating expense 21,198 57,763 427,563 Operating loss (8,357) (41,197) (428,934)Interest expense (1,740) (1,740) (1,737)Other income, net 2,006 2,768 4,294 Loss before income taxes (8,091) (40,169) (426,377)Income tax provision (benefit) 184 202 (302)Net loss$(8,275) $(40,371) $(426,075) Net loss per share: Basic$(0.03) $(0.13) $(1.44)Diluted$(0.03) $(0.13) $(1.44) Weighted average shares outstanding used in calculating net loss per share: Basic 305,819 301,907 296,858 Diluted 305,819 301,907 296,858 (1) Balances for the three months ended December 31, 2005 and March 31, 2025 include restructuring costs. Refer to the Reconciliation of Non-GAAP Financial Measures table below for additional information on such costs and related amounts.
(2) In-process research and development ("IPR&D") impairment charge was driven primarily by macroeconomic factors and restructuring initiatives, including the focus on long-read innovation, resulting in changes to the timing and amounts of cash flows.
(3) Includes litigation settlement charges and related legal fees in connection with the binding term sheet entered into with Personal Genomics of Taiwan, Inc during the three months ended March 31, 2026.
(4) Balances for the three months ended March 31, 2026 Include amounts related to the disposition of short-read assets, including the gain on the sale of certain assets related to our short-read DNA sequencing technology and related clustering, sequencing reagent, and detection technologies, and related non-recurring customer transition costs.
(5) Balance for the three months ended March 31, 2025 includes accelerated amortization of acquired intangible assets related to restructuring initiatives. Refer to the Reconciliation of Non-GAAP Financial Measures table below for additional information on such costs and related amounts.
(6) Change in fair value of contingent consideration was due to fair value adjustments of a milestone payment payable upon the achievement of a milestone event.
Pacific Biosciences of California, Inc.
Unaudited Condensed Consolidated Balance Sheets (in thousands) March 31,
2026 December 31,
2025Assets Cash and investments $275,962 $279,506Accounts receivable, net 29,350 35,448Inventory, net 51,022 49,285Prepaid expenses and other current assets 13,164 10,793Property and equipment, net 24,376 24,146Operating lease right-of-use assets, net 40,846 41,695Restricted cash 1,590 1,552Intangible assets, net 14,104 15,124Goodwill 317,761 317,761Other long-term assets 14,190 8,773Total Assets $782,365 $784,083 Liabilities and Stockholders' Equity Accounts payable $13,609 $20,770Accrued expenses 33,904 33,646Deferred revenue 19,884 19,865Operating lease liabilities 59,281 57,040Convertible senior notes, net 644,107 645,382Other liabilities 9,214 2,031Stockholders' equity 2,366 5,349Total Liabilities and Stockholders' Equity $782,365 $784,083 Pacific Biosciences of California, Inc.
Reconciliation of Non-GAAP Financial Measures
Three Months Ended(in thousands, except per share amounts) March 31,
2026 December 31,
2025 March 31,
2025GAAP net loss $(8,275) $(40,371) $(426,075)Change in fair value of contingent consideration(1) — — (18,700)Settlement charges(2) 16,804 — — Amortization of acquired intangible assets 1,016 1,016 7,128 Disposition of short-read assets(3) (45,490) — — Income tax benefit(4) — — (546)Restructuring(5) — 1,776 393,788 Non-GAAP net loss $(35,945) $(37,579) $(44,405) GAAP basic net loss per share $(0.03) $(0.13) $(1.44)Change in fair value of contingent consideration(1) — — (0.06)Settlement charges(2) 0.05 — — Amortization of acquired intangible assets — — 0.02 Disposition of short-read assets(3) (0.15) — — Restructuring(5) — 0.01 1.33 Other adjustments and rounding differences 0.01 — — Non-GAAP basic net loss per share $(0.12) $(0.12) $(0.15) GAAP gross profit (loss) $12,841 $16,566 $(1,371)Amortization of acquired intangible assets 183 183 4,345 Settlement charges(2) 500 — — Disposition of short-read assets(3) 306 — — Restructuring(5) — 1,072 12,027 Non-GAAP gross profit $13,830 $17,821 $15,001 GAAP gross profit (loss) % 35% 37% (4)% Non-GAAP gross profit % 37% 40% 40% GAAP total operating expense $21,198 $57,763 $427,563 Change in fair value of contingent consideration(1) — — 18,700 Settlement charges(2) (16,304) — — Amortization of acquired intangible assets (833) (833) (2,783)Disposition of short-read assets(3) 45,796 — — Restructuring(5) — (704) (381,761)Non-GAAP total operating expense $49,857 $56,226 $61,719 (1) Change in fair value of contingent consideration was due to fair value adjustments of a milestone payment payable upon the achievement of a milestone event.
(2) Includes litigation settlement charges and related legal fees in connection with the binding term sheet entered into with Personal Genomics of Taiwan, Inc.
(3) Balance includes amounts related to the disposition of short-read assets, including the gain on the sale of certain assets related to our short-read DNA sequencing technology and related clustering, sequencing reagent, and detection technologies, and related non-recurring customer transition costs.
(4) A deferred income tax benefit during the three months ended March 31, 2025 is primarily related to the change in the deferred tax liability balance resulting from the accelerated amortization of acquired intangible assets and impairment of IPR&D.
(5) Restructuring-related costs incurred in connection with the 2025 plan during the three months ended December 31, 2025 and March 31, 2025 consist primarily of costs included in cost of revenue related to excess inventory and purchase commitment losses, as well as costs included in operating expenses related to employee separation, accelerated depreciation, IPR&D impairment, and accelerated amortization of acquired intangibles.
Pacific Biosciences of California (PACB - Free Report) came out with a quarterly loss of $0.12 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to a loss of $0.15 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of +29.41%. A quarter ago, it was expected that this maker of genetic analysis technology would post a loss of $0.19 per share when it actually produced a loss of $0.12, delivering a surprise of +36.84%.
Over the last four quarters, the company has surpassed consensus EPS estimates four times.
Pacific Biosciences, which belongs to the Zacks Medical - Instruments industry, posted revenues of $37.18 million for the quarter ended March 2026, missing the Zacks Consensus Estimate by 9.32%. This compares to year-ago revenues of $37.15 million. The company has topped consensus revenue estimates two times over the last four quarters.
The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.
Pacific Biosciences shares have lost about 8.6% since the beginning of the year versus the S&P 500's gain of 7.6%.
What's Next for Pacific Biosciences?While Pacific Biosciences has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?
There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.
Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.
Ahead of this earnings release, the estimate revisions trend for Pacific Biosciences was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is -$0.13 on $43.7 million in revenues for the coming quarter and -$0.54 on $175.4 million in revenues for the current fiscal year.
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Instruments is currently in the bottom 41% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.
Another stock from the same industry, CVRx (CVRX - Free Report) , has yet to report results for the quarter ended March 2026. The results are expected to be released on May 11.
This medical device company is expected to post quarterly loss of $0.51 per share in its upcoming report, which represents a year-over-year change of +3.8%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days.
CVRx's revenues are expected to be $14.24 million, up 15.3% from the year-ago quarter.
Key Takeaways PacBio posted a narrower Q1 adjusted loss of 12 cents per share, beating estimates by 29.4%.PACB's consumables revenue rose 9%, while instrument revenue fell 12% year over year.PacBio lowered 2026 revenue guidance to $165M-$175M from the prior $165M-$180M range. Pacific Biosciences of California, Inc. (PACB - Free Report) , popularly known as PacBio, delivered an adjusted loss per share of 12 cents in first-quarter 2026, narrower than the year-ago adjusted loss of 15 cents per share. The adjusted loss per share topped the Zacks Consensus Estimate by 29.4%.
The company’s GAAP loss per share was 3 cents in the quarter compared with the year-ago period’s loss of $1.44.
PacBio’s Revenues in DetailPacBio registered total revenues of $37.2 million in the first quarter, flat year over year. The figure missed the Zacks Consensus Estimate by 9.3%.
Shares of the company lost around 4% in yesterday’s trading session.
PACB’s Geographical AnalysisPacBio’s revenues from the Americas were $16.7 million, up 2%year over year.
In the Asia-Pacific region, PacBio recorded revenues of $9.7 million, reflecting a 16% decrease year over year.
The Europe, the Middle East and Africa (EMEA) region registered revenues of $10.8 million, which improved 17% year over year.
PacBio’s Segmental AnalysisTotal Product revenues amounted to $31.5 million, up 1.4% from the year-ago quarter.
Within the Product segment, Instrument revenues were $9.7 million, down 12% year over year.Instrument revenues in the first quarter of 2026 included 15 Revio sequencing systems and 27 Vega sequencing systems.
PACB ended the quarter with 346 cumulative Revio system shipments and 174 cumulative Vega system shipments.
Consumables revenues for the first quarter of 2026 were $21.8 million, up 9% from the prior-year quarter. AnnualizedRevio pull-through per system was $229,000 in the quarter.
Service and other revenues totaled $5.6million, down 6.6% year over year.
PACB’s Margin TrendIn the quarter under review, PacBio’s adjusted gross profit decreased 8% year over year to $13.8 million. The adjusted gross margin contracted 300 basis points to 37%.
Sales, general and administrative expenses declined 22.5% year over year to $31.2 million. Research and development expenses decreased 32.5% year over year to $19.6 million. Adjusted total operating expenses of $49.9 million decreased 19.1% year over year.
Total operating loss was $8.4 million in the reported quarter compared with the prior-year quarter’s $428.9 million.
PacBio’s Financial PositionPacBio exited the first quarter of 2026 with cash and investmentsof $275.9million compared with $279.5million at the end of the fourth quarter of 2025.
PACB’s 2026 GuidancePacBio has updated its revenue outlook for 2026.
Management now expects 2026 revenues to grow in the range of 3%-9% year over year to $165-175 million compared with the earlier guidance of $165-180 million.The Zacks Consensus Estimate is pegged at $175.4 million.
Our TakePacBio exited the first quarter of 2026 with mixed results, wherein earnings beat the Zacks Consensus Estimate while revenues missed the same. Stable top-line performance, despite softer instrument sales, reflected continued strength in consumables demand and improving utilization trends across the installed base. Growth in consumables revenues, expansion across the EMEA region and disciplined expense management were encouraging. The company also reported a significantly narrower operating loss year over year, supported by lower operating expenses and continued restructuring benefits.
During the quarter, PacBio continued strengthening its long-read sequencing franchise through a series of strategic commercial and technology initiatives. The company was selected by Basecamp Research to support its Trillion Gene Atlas project, expected to deeply sequence nearly 100,000 samples globally, while a new collaboration with DNAstack aims to build the first federated HiFi whole genome dataset. PacBio also expanded its SPRQ-Nx beta program following positive customer feedback and broadened its ecosystem partnerships through an agreement with Lucid Genomics for tertiary analysis compatibility. Complementing these growth initiatives, the company completed the sale of its short-read sequencing assets for net cash proceeds of approximately $48.1 million, further strengthening the balance sheet and extending its cash runway.
PacBio’s Zacks Rank and Stocks to ConsiderPACB currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks from the broader medical space that are expected to report earnings soon are DexCom, Inc. (DXCM - Free Report) , Encompass Health Corporation (EHC - Free Report) and The Cooper Companies, Inc. (COO - Free Report) .
The Zacks Consensus Estimate for DexCom’s first-quarter 2026 adjusted earnings per share (EPS) is currently pegged at 47 cents. The consensus estimate for revenues is pegged at $1.18 billion. DXCM currently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
DexCom has an estimated long-term growth rate of 20.6%. DXCM’s earnings yield of 4.1% compares favorably with the industry’s negative yield.
Encompass Health currently has a Zacks Rank #2. The Zacks Consensus Estimate for its first-quarter 2026 adjusted EPS is currently pegged at $1.51. The same for revenues is pegged at $1.57 billion.
Encompass Health has an estimated long-term growth rate of 8.8%. EHC’s earnings yield of 5.9% compares favorably with the industry’s 5.6%.
Cooper Companies currently carries a Zacks Rank #2. The Zacks Consensus Estimate for its second-quarter fiscal 2026 adjusted EPS is currently pegged at $1.10. The same for its revenues is pegged at $1.05 billion.
Cooper Companies has an estimated long-term growth rate of 8.4%. COO’s earnings yield of 7.2% compares favorably with the industry’s 6.1%.
MarketBeat Instant News Alerts Trending News All MarketBeat Instant News Alerts Sort By
Time Frame
Alert Type
Keywords
Page 1 of 322
Get 30 Days of MarketBeat All Access for Free
Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools.
Start Your 30-Day Trial
Sign in to your free account to enjoy these benefits
In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer.
Multinational study shows how one comprehensive genomic workflow and secure data collaboration may help reduce fragmented testing for couples seeking answers Multinational study shows how one comprehensive genomic workflow and secure data collaboration may help reduce fragmented testing for couples seeking answers
SAN FRANCISCO--(BUSINESS WIRE)--Blank Bio Announces Seed Financing and Strategic Collaboration with PacBio to Advance RNA Foundation Models for Precision Oncology.
Key Takeaways PACB teamed with Blank Bio to generate HiFi long-read bulk RNA-seq data from tumors.PACB work targets up to 100 fresh-frozen tumor samples across multiple cancer indications.PACB says HiFi long reads can resolve complex tumor transcriptomes that conventional methods may miss. Pacific Biosciences of California (PACB - Free Report) , also known as PacBio, recently entered a collaboration with Blank Bio, an applied AI research company focused on RNA foundation models for precision oncology. The collaboration accompanies PACB’s $7.2 million seed financing in Blank Bio to support model development and partnership expansion. Blank Bio will use PacBio’s HiFi long-read sequencing technology to generate bulk RNA sequencing data from patient tumor samples across multiple cancer indications.
PacBio Management noted that its HiFi long-read sequencing technology is built to resolve complex transcriptomes of tumors that conventional sequencing approaches may miss. The company underscored that Blank Bio’s foundation models show how high-resolution RNA sequencing and machine learning can strengthen precision oncology applications, including biomarker discovery, diagnostics and clinical trial design.
Likely Trend of PACB Stock Following the NewsFollowing the announcement, the company's shares traded flat at yesterday’s closing. In the year-to-date period, the stock has declined 38.5% compared with the industry’s 18.8% fall. However, the S&P 500 has risen 9% in the same timeframe.
The collaboration with Blank Bio strengthens PacBio’s competitive standing in the oncology market. It also expands the use of its HiFi long-read sequencing technology in AI-driven precision medicine applications. Rising adoption of long-read sequencing across clinical research and biomarker development could support PacBio’s long-term growth in advanced sequencing technologies.
PACB currently has a market capitalization of $357.2 million.
Image Source: Zacks Investment Research
More on the NewsUnder the collaboration, Blank Bio will generate PacBio HiFi long-read, bulk RNA sequencing data from up to 100 fresh frozen tumor samples spanning multiple cancer types. Sequencing activities will be conducted at Seattle Children’s Research Institute using Kinnex RNA libraries on the SPTLabtech firefly+ platform.
Bulk RNA sequencing is being adopted ever more across oncology research as it provides insight into the molecular state of tumors at scalable costs. Traditional analysis methods often compress RNA-seq data into per-gene count summaries, limiting the ability to capture isoform diversity and patient-specific tumor biology.
PacBio believes its HiFi long-read sequencing technology will help address these limitations by delivering comprehensive transcriptomic information. The collaboration with Blank Bio is expected to support the development of next-generation AI models capable of improving patient stratification, biomarker discovery and clinical interpretation in oncology.
Industry Prospects Favoring the MarketGoing by the data provided by Precedence Research, the U.S.-targeted DNA/RNA sequencing market was valued at $5.73 billion in 2026 and is expected to witness a CAGR of 19.2% through 2035.
Factors like the rising cancer incidences, increasing focus on oncology, growth of precision medicine and rising trend for early disease detection are boosting the market’s growth.
Other NewsPacBio reported mixed first-quarter 2026 results, wherein earnings beat the Zacks Consensus Estimate while revenues missed the same. Stable revenues were supported by strong consumables demand, improving utilization trends and growth in the EMEA region, while operating losses narrowed due to lower expenses and restructuring benefits. During the quarter, PacBio strengthened its long-read sequencing business through collaborations with Basecamp Research, DNAstack and Lucid Genomics, expanded its SPRQ-Nx beta program and completed the sale of its short-read sequencing assets for approximately $48.1 million in net cash proceeds.
PACB’s Zacks Rank & Other Key PicksPacBio currently carries a Zacks Rank #2 (Buy).
Some other top-ranked stocks from the broader medical space are West Pharmaceutical (WST - Free Report) , Globus Medical (GMED - Free Report) and Intuitive Surgical (ISRG - Free Report) .
West Pharmaceutical, sporting a Zacks Rank #1 (Strong Buy) at present, reported first-quarter 2026 earnings per share (EPS) of $2.13, which beat the Zacks Consensus Estimate by 26.8%. Revenues of $844.9 million surpassed the Zacks Consensus Estimate by 8.5%. You can see the complete list of today’s Zacks #1 Rank stocks here.
West Pharmaceutical has an estimated long-term earnings growth rate of 13.9%. WST’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 19.4%.
Globus Medical, currently carrying a Zacks Rank #2, reported first-quarter 2026 adjusted EPS of $1.12, which surpassed the Zacks Consensus Estimate by 22.1%. Revenues of $759.9 million beat the Zacks Consensus Estimate by 4.0%.
Globus Medical has an estimated long-term earnings growth rate of 10.2%. GMED’s earnings beat estimates in each of the trailing four quarters, the average surprise being 26.3%.
Intuitive Surgical, carrying a Zacks Rank #2 at present, reported first-quarter 2026 adjusted EPS of $2.50, which beat the Zacks Consensus Estimate by 20.2%. Revenues of $2.77 billion surpassed the Zacks Consensus Estimate by 6.2%.
Intuitive Surgical has a long-term estimated growth rate of 14.6%. ISRG’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 16.8%.
MENLO PARK, Calif., May 21, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, announced today that management will participate in a fireside chat at the Jefferies’ Global Healthcare Conference on Thursday, June 4, 2026, at 2:00 PM ET in New York, New York.
A live webcast of the event can be accessed at the company’s investors page at investor.pacificbiosciences.com. A replay of the webcast will be available for at least 30 days following the event.
About PacBio
PacBio (NASDAQ: PACB) is a premier life science technology company that designs, develops, and manufactures advanced sequencing solutions to help scientists and clinical researchers resolve genetically complex problems. Our products and technologies, which include our HiFi long-read sequencing, address solutions across a broad set of research applications including human germline sequencing, plant and animal sciences, infectious disease and microbiology, oncology, and other emerging applications. For more information, please visit www.pacb.com and follow @PacBio.
PacBio products are provided for Research Use Only. Not for use in diagnostic procedures.
New Revio multi-use SMRT Cells reduce sequencing costs by 30% compared to previous SPRQ chemistry while DeepConsensus improvements and expanded methylation calling increase accuracy, yield, and epigenetic insight May 26, 2026 09:05 ET | Source: PacBio
MENLO PARK, Calif., May 26, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), developer of the world’s most advanced sequencing technologies, today announced that SPRQ-Nx sequencing chemistry and new multi-use SMRT Cells for its Revio HiFi sequencing platform are now shipping worldwide. The commercial availability of SPRQ-Nx brings the per genome list price to $345, and the possibility of sub-$300 HiFi genomes to Revio customers sequencing at scale1, while expanded methylation detection and advances to DeepConsensus, an AI powered consensus algorithm developed in collaboration with Google, further improve accuracy, run performance, and the biological information generated from each read.
PacBio has continued expanding the use of AI across the HiFi sequencing workflow in ways that directly improve data quality, speed, and biological interpretation. The latest DeepConsensus updates include optimizations enabled by Google’s AlphaEvolve coding agent, delivering measurable gains in accuracy and processing speed. PacBio is also advancing deep learning models for epigenetic detection, including updated 5mC and 6mA models optimized for SPRQ-Nx chemistry and a new 5-hydroxymethyl-cytosine, or 5hmC, caller. These advances are designed to help researchers generate richer HiFi datasets from the same sequencing run, including methylation signals relevant to cancer, tissue sequencing, and large-scale genomic research.
When paired with SPRQ-Nx chemistry, these improvements translate directly to lower costs and higher performance in production environments. SPRQ-Nx allows the SMRT Cell consumable to be used multiple times, reducing sequencing costs to less than $300 per human genome at scale. In beta testing across 20 sites in Europe, Asia, and the United States, spanning over 1,400 runs, SPRQ-Nx delivered increased yield and a lower failure rate across a broad range of sample types, resulting in more usable data and greater consistency for high-throughput workflows relative to SPRQ chemistry.
“In our beta testing, we saw consistently strong run performance,” said Adam Ameur, Associate Professor and Senior Bioinformatician at Uppsala University. “The simple workflow, low failure rates, and substantially lower pricing with multi-use SMRT Cells make SPRQ-Nx a practical upgrade for large-scale sequencing projects.”
“HiFi sequencing already is well known for a high standard of genomic accuracy, and AI is helping us push that advantage further by improving data quality, speed, and usability while expanding what researchers can learn from each run,” said Christian Henry, President and CEO of PacBio. “With SPRQ-Nx, DeepConsensus, and expanded methylation calling working together, Revio customers can generate more information-rich HiFi long-read data at a much lower cost, creating a stronger foundation for population-scale studies, large disease cohorts, and AI-enabled genomic research.”
“The quality of genomic data is determined by the information richness of the sequencer and the refinement of the algorithms that process it,” said Andrew Carroll, Product Lead for Genomics at Google Research. “New advances in DeepConsensus unlock even more of the exceptional quality inherent in HiFi sequencing, empowering scientists and clinicians to find new insights and resolve complex cases of rare disease.”
PacBio is also extending AI across the broader genomics workflow, including downstream analysis and interpretation. As population-scale sequencing efforts, national biobanks, large disease cohorts, and AI model-building initiatives generate growing demand for richer genomic datasets, highly accurate HiFi long-read sequencing can play an important role in producing the data foundation needed for discovery. Initiatives such as the Trillion Genes Atlas project further highlight how HiFi sequencing and AI can support large-scale genomic research and future clinical discovery.
With SPRQ-Nx now shipping globally, PacBio is making HiFi sequencing more scalable for population-scale genomics, large cohort studies, and research programs that require high accuracy, reliability, and richer molecular information. These improvements are available on existing Revio systems through a software upgrade and new consumable kits. PacBio plans to bring SPRQ-Nx chemistry and other platform improvements to its Vega benchtop system later in 2026.
1 Based on 5,000 genomes per year with applicable discounts.
About PacBio
PacBio (NASDAQ: PACB) is a premier life science technology company that designs, develops, and manufactures advanced sequencing solutions to help scientists and clinical researchers resolve genetically complex problems. Our products and technologies, which include our HiFi long-read sequencing, address solutions across a broad set of research applications including human germline sequencing, plant and animal sciences, infectious disease and microbiology, oncology, and other emerging applications. For more information, please visit www.pacb.com and follow @PacBio.
PacBio products are provided for Research Use Only. Not for use in diagnostic procedures.
Forward-Looking Statements
This press release contains "forward-looking statements" within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and the U.S. Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact are forward-looking statements, including statements relating to the uses, advantages, quality or performance of, or benefits or expected benefits of using, PacBio products or technologies, including in connection with the SPRQ-Nx sequencing chemistry and multi-use SMRT Cells; reduction in sequencing costs by as much as 30%; improved methylation calling and epigenetic insight; expanded use of AI across sequencing workflows and related improvements in data quality, speed, and usability; generating richer HiFi datasets from the same sequencing run; possible lower costs in production environments; plans to release SPRQ-Nx chemistry and other platform improvements to the Vega benchtop system later in 2026; and other forward-looking statements. You should not place undue reliance on forward-looking statements because they are subject to assumptions, risks, and uncertainties that could cause actual outcomes and results to differ materially from currently anticipated results, including, challenges inherent in developing, manufacturing, launching, marketing and selling new products; rapidly changing technologies and extensive competition in genomic sequencing; unanticipated increases in costs or expenses; interruptions or delays in the supply of components or materials for, or manufacturing of, PacBio products; potential product performance and quality issues; the possible loss of key suppliers; and, third-party claims alleging infringement of patents and proprietary rights or seeking to invalidate PacBio's patents or proprietary rights. Additional factors that could materially affect actual results can be found in PacBio's most recent filings with the Securities and Exchange Commission, including PacBio's most recent reports on Forms 8-K, 10-K, and 10-Q, and include those listed under the caption "Risk Factors." These forward-looking statements are based on current expectations and speak only as of the date hereof; except as required by law, PacBio disclaims any obligation to revise or update these forward-looking statements to reflect events or circumstances in the future, even if new information becomes available.
PACB expands HiFi sequencing reach with commercial availability of SPRQ-Nx for Revio, lowering costs by about 30% and adding AI and epigenetics upgrades.
An updated edition of the April 13, 2026, article.
Genomics is the comprehensive study of genomes, the complete set of deoxyribonucleic acid (DNA) within an organism. Rapid scientific progress in this field has intensified interest among pharmaceutical and biotechnology companies seeking deeper insight into disease biology and more effective therapeutic strategies.
A key point to note is the difference between genetics and genomics. While genetics focuses on individual genes, genomics primarily aims to characterize all the genes of an organism. Genomics involves understanding how they interact with one another and with environmental factors to influence biological processes.
Insights from genomic research are increasingly being used to evaluate how patients respond to specific drugs. These findings are also driving the development of precise, more targeted treatments, contributing to the advancement of personalized medicine. As demand for innovative therapies continues to grow, genomics is poised to play an increasingly central role in the future of healthcare, despite the complexity inherent in genome-scale research.
The expanding genomics landscape has also supported the growth of synthetic biology, which applies engineering principles to biology. This emerging field involves redesigning organisms for diverse applications, including drug discovery, disease detection, enzyme engineering, gene editing and foundational research.
A key driver of progress in genomics has been the dramatic reduction in the cost, time and technical effort required to sequence an individual’s genome. A prominent player in this field is Illumina (ILMN - Free Report) , widely recognized for its leadership in sequencing and array-based technologies for genetic analysis.
While many companies are using genomic sequencing to create solutions across healthcare and other industries, diagnostic firms are leveraging sequencing data to identify genetic variations and link them to known medical conditions.
Another breakthrough is the development of genome editing approaches, such as CRISPR/Cas9 technology. Gene editing companies, such as CRISPR Therapeutics AG (CRSP - Free Report) and Beam Therapeutics (BEAM - Free Report) , are exploring these tools to develop treatments (and potentially cures) for diseases caused by genetic mutations. By enabling precise modifications to DNA, genome editing offers the possibility of correcting harmful genetic defects at their source.
According to Fortune Business Insights, the global genomics market was valued at $34.23 billion in 2025 and is expected to expand from $38.24 billion in 2026 to $99.26 billion by 2034, reflecting a compound annual growth rate (CAGR) of 12.66% over the period.
Per a Grandview Research article, the global synthetic biology market size was valued at $18.94 billion in 2025 and is projected to reach $69.18 billion by 2033, at a CAGR of 17.7% from 2026 to 2033.
If you're looking to capitalize on this trend, our Genomics and Synthetic Biology screen makes it easy to identify high-potential stocks at any given time. At present, stocks like Pacific Biosciences of California (PACB - Free Report) , Myriad Genetics (MYGN - Free Report) and Twist Biosciences (TWST - Free Report) hold potential.
Explore 37 cutting-edge investment themes with Zacks Thematic Investing Screens and uncover your next big opportunity.
3 Genomics Stocks to ConsiderPacific Biosciences of California is a life science technology company that designs, develops and manufactures advanced sequencing solutions. The company is focused on creating some of the world’s most advanced sequencing systems to provide customers with the most complete and accurate study of genomes, transcriptomes and epigenomes.
PACB’s portfolio, led by its HiFi long-read sequencing technology, supports a wide range of applications spanning human germline sequencing, plant and animal sciences, infectious disease and microbiology, oncology and other emerging fields.
Pacific Biosciences’ customers include academic and governmental research institutions, commercial testing and service laboratories, genome centers, public health labs, hospitals and clinical research institutes, contract research organizations (CROs), pharmaceutical companies and agricultural companies. The company has collaborated with n-Lorem Foundation and EspeRare to advance precision therapies for rare genetic diseases.
PACB’s shares have risen 4% in the last three months. The company currently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Myriad Genetics is a molecular diagnostics and precision medicine company focused on improving patient outcomes through advanced genetic testing. The company develops and commercializes innovative molecular diagnostic solutions that provide genetic insights to patients and healthcare providers. Its tests help evaluate disease risk, predict disease progression, and inform treatment decisions across multiple medical specialties. By enabling earlier detection, more personalized therapies, and better-informed clinical care, Myriad aims to enhance patient outcomes while helping reduce overall healthcare costs.
The company concentrates its expertise and product development efforts across these core areas: Oncology, Women’s Health and Mental Health. In early 2025, MYGN secured exclusive U.S. rights to PATHOMIQ_PRAD through a collaboration with PATHOMIQ, Inc., enhancing its oncology portfolio with AI-driven prostate cancer diagnostics. In September 2025, the company partnered with SOPHiA GENETICS S.A. to develop a global liquid biopsy companion diagnostic solution. The company is also investing in product innovation to support the growth of existing offerings and the launch of new products, including FirstGene and Precise MRD. These efforts strengthen its competitive position, expand its market opportunities, and further differentiate its testing portfolio. Myriad Genetics also carries a Zacks Rank #2 at present.
Twist Biosciences, a synthetic biology company, has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The company leveraged its unique technology to manufacture a broad range of synthetic DNA-based products, including synthetic genes, tools for next-generation sequencing, sample preparation, and antibody libraries for drug discovery and development.
TWST has expanded beyond DNA synthesis into the production of synthetic RNA and antibody proteins, addressing larger market opportunities while supporting biologic drug discovery partnerships.
Its products serve a wide range of applications across healthcare, agriculture, food, chemicals, materials, academic research and technology.
As the company has expanded its offerings from DNA fragments and genes to protein and antibody solutions, the connection between its synthetic biology and biopharma businesses has strengthened.
Revenues are generated from synthetic biology products, NGS tools, and biopharma services, including antibody discovery, optimization and development. The company currently carries a Zacks Rank #3 (Hold).
Key Takeaways PacBio gains from product development and a Q1 earnings beat despite funding challenges.PACB's SPRQ-Nx chemistry boosts yields and targets sub-$300 genome sequencing at scale.PacBio sees research funding uncertainty weighing on Revio and Vega demand through 2026. Pacific Biosciences of California, Inc. (PACB - Free Report) , popularly known as PacBio, has been gaining from its continued product development. The optimism, led by strong first-quarter results, is expected to contribute further. However, concerns about funding headwinds persist.
In the year-to-date period, this Zacks Rank #2 (Buy) company’s shares have lost 17.6% compared with 16.7% decline of the industry. The S&P 500 Composite has improved 11% in the said time frame.
The renowned global provider of sequencing systems has a market capitalization of $490.8 million. The company projects 22.6% growth for 2026 and expects to maintain its strong performance going forward. PacBio’s earnings surpassed the Zacks Consensus Estimate in all the trailing four quarters, delivering an average surprise of 29.8%.
Image Source: Zacks Investment Research
Factors Favoring PACB’s GrowthSequencing Technologies Strengthen Market Leadership: PacBio differentiates itself in the genomics industry through its proprietary HiFi long-read sequencing, based on Single-Molecule Real-Time (SMRT) technology. This technology enables the high-accuracy, real-time detection of complex genomic structures, such as structural variations, haplotypes and epigenetic modifications.
Per a report by Data Bridge Market Research, the global SMRT market size was valued at $2.88 billion in 2024 and is projected to reach $4.36 billion by 2032, at a CAGR of 5.3%. Additionally, PacBio has expanded its offerings by integrating Sequencing by Binding chemistry with the launch of its Onso system in 2022, a short-read platform delivering ≥90% of bases at Q40+ accuracy, 15 times more precise than traditional sequencing methods. By providing both long-read and short-read technologies, PacBio uniquely serves diverse research and clinical applications while driving down costs and enhancing variant detection.
Robust Product Portfolio Driving Growth: PacBio continues to strengthen its competitive position through innovation in its HiFi sequencing platform. The company's SPRQ-Nx chemistry is gaining traction, delivering higher sequencing yields and enabling human whole-genome sequencing costs below $300 at scale through reusable SMRT Cells. Management plans to extend the technology to the Vega platform later this year, enhancing throughput and workflow efficiency.
PacBio is also advancing its next-generation ultra-high-throughput sequencing platform to target large-scale clinical and population genomics opportunities. Additionally, its collaboration with Basecamp Research to sequence roughly 100,000 metagenomic samples highlights the expanding role of HiFi sequencing in AI-driven biological research and underscores the technology's growing adoption across emerging applications.
Strong Q1 Results: PacBio exited the first quarter of 2026 with mixed results, wherein earnings beat the Zacks Consensus Estimate while revenues missed the same. Stable top-line performance, despite softer instrument sales, reflected continued strength in consumables demand and improving utilization trends across the installed base.
Growth in consumables revenues, expansion across the EMEA region and disciplined expense management were encouraging. The company also reported a significantly narrower operating loss year over year, supported by lower operating expenses and continued restructuring benefits.
A Factor That May Offset the Gains for PACBFunding Headwinds Continue to Weigh on Instrument Demand: PacBio continues to face funding-related headwinds that are weighing on instrument demand, particularly across academic and government research markets. Uncertainty around grant funding and cautious capital spending have pressured purchases of both Revio and Vega systems, with Vega being more exposed to academic budget constraints.
While the company is seeing growing interest from clinical and commercial customers, management does not anticipate a meaningful recovery in research funding through 2026 and recently lowered the high end of its annual revenue outlook due in part to weaker instrument demand. Although the upcoming commercial launch of SPRQ-Nx chemistry could improve the attractiveness of PacBio’s sequencing platforms by lowering costs and boosting throughput, near-term instrument growth is expected to remain dependent on expanding clinical adoption rather than a broad recovery in research spending.
Estimate TrendPacBio has been witnessing a positive estimate revision trend for 2026. Over the past 30 days, the Zacks Consensus Estimate for its adjusted loss per share has narrowed by 13 cents to 41 cents.
The Zacks Consensus Estimate for 2026 revenues is pegged at $165.8 million, indicating a 3.6% increase from the year-ago reported numbers.
Other Key PicksSome other top-ranked stocks from the broader medical space are Globus Medical (GMED - Free Report) , West Pharmaceutical (WST - Free Report) and Intuitive Surgical (ISRG - Free Report) .
Globus Medical, currently flaunting a Zacks Rank #1 (Strong Buy), reported a first-quarter 2026 adjusted earnings per share (EPS) of $1.12 per share, which surpassed the Zacks Consensus Estimate by 22.1%. Revenues of $759.9 million beat the Zacks Consensus Estimate by 4.0%. You can see the complete list of today’s Zacks #1 Rank stocks here.
GMED has an estimated long-term earnings growth rate of 10.2% compared with the industry’s 12.6% growth. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 26.3%.
West Pharmaceutical, currently sporting a Zacks Rank #1, reported first-quarter 2026 EPS of $2.13, which beat the Zacks Consensus Estimate by 26.8%. Revenues of $844.9 million surpassed the Zacks Consensus Estimate by 8.5%.
WST has an estimated long-term earnings growth rate of 13.9% compared with the industry’s 9.5% growth. The company’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 19.4%.
Intuitive Surgical, carrying a Zacks Rank #2 at present, reported first-quarter 2026 adjusted EPS of $2.50, which beat the Zacks Consensus Estimate by 20.2%. Revenues of $2.77 billion surpassed the Zacks Consensus Estimate by 6.2%.
ISRG has a long-term estimated growth rate of 14.6% compared with the industry’s 12.6% growth. The company’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 16.8%.
